Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia

Aim: This study evaluates the cost–effectiveness of imipenem/cilastatin/relebactam (IMI/REL) for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in an ‘early adjustment prescribing scenario’. Methods: An economic model was constructed to com...

Full description

Bibliographic Details
Main Authors:	Jaesh Naik, Ryan Dillon, Matthew Massello, Lewis Ralph, Zhuo Yang
Format:	Article
Language:	English
Published:	Becaris Publishing Limited 2023-01-01
Series:	Journal of Comparative Effectiveness Research
Subjects:	antimicrobial resistance cost–effectiveness analysis culture and susceptibility habp/vabp health economics imipenem/cilastatin/relebactam infectious diseases

Similar Items

Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials
by: Qingxin Yang, et al.
Published: (2023-12-01)

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
by: Dai Kurihara, et al.
Published: (2022-04-01)

In vitro study of the embolic characteristics of imipenem/cilastatin particles
by: Hiroki Nakamura, et al.
Published: (2024-03-01)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
by: Soo Min Jang, et al.
Published: (2021-09-01)

Effect of Oxygen and Water on the Stability of Imipenem and Cilastatin Sodium for Injection
by: Meng Zhang, et al.
Published: (2022-06-01)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
by: Mervat Mashaly, et al.
Published: (2022-02-01)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
by: Mervat Mashaly, et al.
Published: (2022-06-01)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
by: Mervat El-Sayed Mashaly, et al.
Published: (2021-12-01)

Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa
by: Mario López-Pérez, et al.
Published: (2021-12-01)

Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy
by: Matilde Zaballos, et al.
Published: (2021-01-01)

Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan
by: Tsung-Ying Yang, et al.
Published: (2022-02-01)

Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)
by: Marta Hernández-García, et al.
Published: (2022-10-01)

Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients
by: Xi You, et al.
Published: (2024-03-01)

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
by: Özlem AYDEMİR, et al.
Published: (2023-09-01)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
by: Leilei Wang, et al.
Published: (2023-06-01)

Determination of Antimicrobial Resistance and the Impact of Imipenem + Cilastatin Synergy with Tetracycline in <i>Pseudomonas aeruginosa</i> Isolates from Sepsis
by: Telma de Sousa, et al.
Published: (2023-11-01)

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: a single-center retrospective study
by: Sakiko Hiraki, et al.
Published: (2023-03-01)

Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem
by: Marin H. Kollef, et al.
Published: (2022-12-01)

Transcatheter arterial embolization using imipenem/cilastatin sodium and microspheres for traumatic pseudoaneurysm: A case report
by: Takaki Hirano, et al.
Published: (2022-12-01)

Efficacy and safety of novel carbapenem–β-lactamase inhibitor combinations: Results from phase II and III trials
by: Wei Yu, et al.
Published: (2022-09-01)

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial
by: Jean-François Timsit, et al.
Published: (2021-08-01)

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
by: Katherine Young, et al.
Published: (2019-07-01)

A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China
by: Chen Y, et al.
Published: (2018-11-01)

In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates
by: Dan Li, et al.
Published: (2023-12-01)

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020
by: James A. Karlowsky, et al.
Published: (2023-05-01)

Comparison of the inoculum effect of in vitro antibacterial activity of Imipenem/relebactam and Ceftazidime/avibactam against ESBL-, KPC- and AmpC-producing Escherichia coli and Klebsiella pneumoniae
by: Xueting Wang, et al.
Published: (2023-12-01)

Small bowel bleeding treated successfully with transcatheter arterial embolization with imipenem/cilastatin
by: Takahiro Arima, et al.
Published: (2022-01-01)

Rapid Detection of KPC-Producing Enterobacterales Susceptible to Imipenem/Relebactam by Using the MALDI-TOF MS MBT STAR-Carba IVD Assay
by: Marina Oviaño, et al.
Published: (2020-02-01)

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
by: Helio S. Sader, et al.
Published: (2021-12-01)

Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient
by: Paolo Gaibani, et al.
Published: (2022-04-01)

Mycobacterium abscessus skin and soft tissue infection following autologous fat grafting in Kurdistan treated with an antibiotic combination including Imipenem-Relebactam and Rifabutin
by: Alison J. Beech, et al.
Published: (2023-08-01)

<i>Klebsiella pneumoniae</i> Susceptibility to Carbapenem/Relebactam Combinations: Influence of Inoculum Density and Carbapenem-to-Inhibitor Concentration Ratio
by: Maria V. Golikova, et al.
Published: (2022-06-01)

In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancer
by: Kenneth V.I. Rolston, et al.
Published: (2022-06-01)

Feasibility of Neovessel Embolization in a Large Animal Model of Tendinopathy: Safety and Efficacy of Various Embolization Agents
by: Julien Ghelfi, et al.
Published: (2022-09-01)

Successful treatment of multiple microbleeds in a large area of the small bowel by transcatheter arterial embolization using imipenem/cilastatin as embolization material
by: Sakiko Hiraki, MD, et al.
Published: (2023-09-01)

Cilastatin protects against tacrolimus-induced nephrotoxicity via anti-oxidative and anti-apoptotic properties
by: Kang Luo, et al.
Published: (2019-06-01)

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase
by: Krisztina M. Papp-Wallace, et al.
Published: (2023-05-01)

In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015–2017
by: James A. Karlowsky, et al.
Published: (2020-06-01)

The Pattern of Imipenem/Cilastatin Administration in Imam Khomeini Hospital (Ardabil) in 2018
by: Moien Zakavati, et al.
Published: (2019-04-01)

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia
by: Munjal Patel, et al.
Published: (2022-02-01)